Title:
抗腫瘍剤
Document Type and Number:
Japanese Patent JP4287523
Kind Code:
B2
Abstract:
PROBLEM TO BE SOLVED: To obtain an antitumor agent highly effective for treating cancer by using dolastatin 10 in combination with other specific compound(s). SOLUTION: This antitumor agent is obtained by using (A) dolastatin 10 or an analog thereof (e.g. a compound of the formula) as an active ingredient in combination with (B) an antitumor agent with, as another kind of active ingredient, at least one compound selected from the group consisting of 5- fluorouracil, doxorubicin, irinotecan, cisplatin, cyclophosphamide, etoposide, and paclitaxel; wherein the ingredient B is pref. 0.1-50 wt.% in content when this antitumor agent is in a solid or semi-solid form, being pref. 0.05-10 wt.% in concentration when the antitumor agent is in a liquid form. The dose of the ingredient A is normally about 0.1 - about 10 mg, pref. about 0.2 - about 5 mg, at one time, while the dose of the ingredient B, depending on the kind, for example, for 5-fluorouracil, is normally about 5 - about 20 mg at one time.
Inventors:
Apparently Takashi
Motohiro Kobayashi
Natsume Shaoryu
Junichi Watanabe
Koichi Miyazaki
Motohiro Kobayashi
Natsume Shaoryu
Junichi Watanabe
Koichi Miyazaki
Application Number:
JP37347598A
Publication Date:
July 01, 2009
Filing Date:
December 28, 1998
Export Citation:
Assignee:
Aska Pharmaceutical Co., Ltd.
International Classes:
A61K38/00; A61K31/00; A61K31/335; A61K31/337; A61K31/365; A61K31/505; A61K31/66; A61K31/70; A61K31/7028; A61K31/7034; A61K31/704; A61K31/7042; A61K31/7048; A61K33/24; A61P35/00; A61P43/00
Foreign References:
| WO1998040092A1 |
Other References:
日本癌治療学会誌,1996年,31, 3,p.163-170
MOHAMMAD,R.M. et al,An orthotopic model of human pancreatic cancer in severe combined immunodeficient mice: potential application for preclinical studies,Clinical cancer research : an official journal of the American Association for Cancer Research,1998年 4月,Vol.4, No.4,p.887-94
MOHAMMAD,R.M. et al,Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1,Clinical Cancer Research,1998年 5月,Vol.4, No.5,p.1337-1343
MOHAMMAD,R.M. et al,An orthotopic model of human pancreatic cancer in severe combined immunodeficient mice: potential application for preclinical studies,Clinical cancer research : an official journal of the American Association for Cancer Research,1998年 4月,Vol.4, No.4,p.887-94
MOHAMMAD,R.M. et al,Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1,Clinical Cancer Research,1998年 5月,Vol.4, No.5,p.1337-1343
Attorney, Agent or Firm:
Patent business corporation Odashima patent office
Youji Esumi
Heigo Odashima
Youji Esumi
Heigo Odashima